Defibrotide for Patients with Hepatic Veno-Occlusive Disease

Protocol
08-060
Full Title
Defibrotide for Patients with Hepatic Veno-Occlusive Disease(VOD): A Treatment IND Study
Purpose

Veno-occlusive disease (VOD) is an inflammatory condition caused by the high-dose chemotherapy used to condition patients before stem cell transplants. The therapy damages blood vessels and cells in the liver and leads to pain, build up of fluid in the body, and abnormal liver function.

Defibrotide is an investigational drug being studied as a possible treatment for VOD. Defibrotide has been used in the past to treat kidney loss after kidney transplantation, to lower blood vessel inflammation, and to treat VOD in blood stem cell transplant patients. These studies show that defibrotide cures severe VOD in about 40 percent of patients. The purpose of this study is to evaluate the safety and effectiveness of defibrotide as a possible treatment for VOD.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patient must have a diagnosis of veno-occlusive disease.

For more information and to inquire about eligibility for this study, please contact Dr. Nancy A. Kernan at 212-639-7250.

Disease(s)
Blood and Marrow Transplantation: Transplantation
Locations

Cancer Clinical Trials: Personalizing for Each Patient

Join our experts for a discussion of clinical trials on November 18. Clinical trials can give patients access to new drugs and other treatments before they are widely available, but how do you know if a trial is right for you?

Learn more »